

**Name of journal:** *World Journal of Clinical Oncology*

**ESPS Manuscript NO:** 19752

Response to the Reviewers:

**Rev. # 00608223**

#1: One minor criticism is that I do not think it is necessary to mention the manufacturer of each drug under development (e.g. Roche and Pfizer are mentioned a few times).

[Response: I removed all but one manufacturers' citations in the text. I think it is good to mention at least once.](#)

**Rev. # 02494537**

#1 Page 1: last line: I recommend the author to add QTc prolongation and esophageal ulceration as the toxicities of crizotinib.

[Response: Added.](#)

#2 Page 3: line 2: I recommend the author to add the updated data of the phase II trial (AF-001JP) of alectinib

[Response: Added most recent data from ASCO 2015.](#)